Logo

Takeda’s Nuvaxovid COVID-19 Vaccine Receives the MHLW Approval for the Treatment of COVID-19

Share this
Takeda’s Nuvaxovid COVID-19 Vaccine Receives the MHLW Approval for the Treatment of COVID-19

Takeda’s Nuvaxovid COVID-19 Vaccine Receives the MHLW Approval for the Treatment of COVID-19

Shots:

  • The approval was based on the interim results from a P-I/II study conducted by Takeda in Japan, multiple studies conducted by Novavax including 2 P-III trials in the US, UK & Mexico along with P-I/II studies in Australia & the US for COVID-19
  • The results from the P-I/II study in Japan were positive & consistent with the prior reported trials with no serious AEs & were well-tolerated while safety & efficacy data will support booster immunization including a P-II study conducted by Novavax in South Africa evaluating a booster dose after primary immunization
  • Takeda had received funding for the technology transfer and R&D to manufacturing Nuvaxovid at the Hikari facility & will initiate distribution in Japan shortly

Ref: Businesswire | Image: Takeda

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions